Skip to Content
October 22, 2013 Jonathan D. Sasser Leslie C. Packer Paul K. Sun, Jr.
Posted in  General

Ellis & Winters “Highly Recommended” by Benchmark Litigation 2014

Ellis & Winters LLP is pleased to announce that five of the firm’s lawyers have been listed as “litigation stars” in Benchmark Litigation’s 2014 edition. Benchmark Litigation’s list of “litigation stars” for each state reflects only those individuals who were recommended consistently as reputable and effective litigators by clients and peers. The […]

Read More
October 16, 2013 Alex J. Hagan
Posted in  General

Alex Hagan Appointed Vice Chair of Defense Research Institute Medical Liability and Health Care Committee

Alex J. Hagan Ellis & Winters partner Alex J. Hagan was recently appointed Vice-Chair of the Medical Liability and Health Care Law Committee of the Defense Research Institute. For more than fifty years, DRI has been the voice of the defense bar, advocating for 22,000 defense attorneys, commercial trial attorneys, and corporate counsel and […]

Read More
October 15, 2013
Posted in  General

Stephen Feldman Appointed to Appellate Practice Section Council of North Carolina Bar Association

Stephen D. Feldman Ellis & Winters partner Stephen D. Feldman has been appointed to the Appellate Practice Section Council of the North Carolina Bar Association (NCBA). The NCBA’s Appellate Practice Section brings together association members who have a special interest in appellate practice, provides networking and educational opportunities in appellate practice, and promotes excellence […]

Read More
September 24, 2013
Posted in  News

D.A.R.E. to Market Off-Label Uses of Prescription Drugs? Make Sure You are in the Second Circuit:United States v. Caronia and the New Off-Label Landscape

Truthful, non-misleading off-label promotion of prescription drugs is not illegal. At least, not in the Second Circuit. This, despite the billions of dollars in civil and criminal penalties assessed against pharmaceutical manufacturers for the promotion of non-FDA approved, or “off-label,” uses for prescription drugs. In United States v. Caronia, 703 F.3d […]

Read More